Registered Plan Private Investments Inc. Stock price

Equities

LXGTF

CA5290204067

Medical Equipment, Supplies & Distribution

Delayed OTC Markets 01:47:28 2024-03-28 pm EDT 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Registered Plan Private Investments Inc. 0.00% 0.00%
Sales 2021 - Sales 2022 - Capitalization 36.58
Net income 2021 - Net income 2022 - EV / Sales 2021 -
Net cash position 2021 664 Net cash position 2022 * - EV / Sales 2022 -
P/E ratio 2021
-
P/E ratio 2022
-
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 13.79%
More Fundamentals * Assessed data
Dynamic Chart
Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Lexington Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Lexington Biosciences, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
More news
1 year
0.00
Extreme 0
0.00
3 years
0.00
Extreme 0
0.10
5 years
0.00
Extreme 0
0.60
10 years
0.00
Extreme 0
4.84
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-04-15
Director of Finance/CFO 66 16-12-20
Members of the board TitleAgeSince
Director of Finance/CFO 66 16-12-20
Director/Board Member - -
More insiders
Date Price Change Volume
24-03-28 0.000001 0.00% 100

Delayed Quote OTC Markets, March 28, 2024 at 01:47 pm EDT

More quotes
Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a person's vascular endothelium - the vital innermost lining of a person's cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health.
More about the company
  1. Stock
  2. Equities
  3. Stock Registered Plan Private Investments Inc. - OTC Markets